Treatment of Heart Failure With Preserved Ejection Fraction
Open Access
- 1 April 2016
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 1 (1) , 7-8
Abstract
This Viewpoint discusses management of heart failure with preserved ejection fraction (HFpEF) and lessons learned from the Treatment of Preserved Cardiac FunctiKeywords
This publication has 7 references indexed in Scilit:
- Faculty Opinions recommendation of Spironolactone for heart failure with preserved ejection fraction.2016
- Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic ReviewJournal of the American Heart Association, 2015
- Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialCirculation, 2015
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection FractionCirculation: Heart Failure, 2010
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Anti-Aldosterone Treatment and the Prevention of Myocardial Fibrosis in Primary and Secondary HyperaldosteronismJournal of Molecular and Cellular Cardiology, 1993